- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07172659
- Juicio original
Estudio de eficacia y seguridad de Dovramilast en personas con reacción de lepra tipo 2
Un estudio de seguridad y eficacia de 12 semanas, abierta, aleatorizado, controlado por la atención, de seguridad de la dosis de Dovramilast en personas con reacción de Lepra Tipo 2 aguda o recurrente moderada a severa
Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Abomey-Calavi, Benín
- Aún no reclutando
- Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli
-
-
-
-
-
Divo, Costa de Marfil
- Aún no reclutando
- Chr de Divo
-
-
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- Reclutamiento
- Harborview Medical Center, University of Washington
-
Contacto:
- Dr Jason Simmons, MD, PhD
- Número de teléfono: 206-744-5463
- Correo electrónico: jasonds@uw.edu
-
-
-
-
-
Manila, Filipinas
- Reclutamiento
- Philippine General Hospital, University of the Philippines, Manila
-
Contacto:
- Dofitas
- Número de teléfono: 63285548400
- Correo electrónico: bldofitas@up.edu.ph
-
-
-
-
-
Yogyakarta, Indonesia
- Reclutamiento
- Universitas Gadjah Mada
-
Contacto:
- Shinta Trilaksmi Dewi, MD, PhD
- Número de teléfono: +6282137381045
- Correo electrónico: shinta.trilaksmi.d@ugm.ac.id
-
-
-
-
-
Tôlanaro, Madagascar
- Reclutamiento
- Programme national lutte contre la lèpre
-
Contacto:
- Andrinamira Randrianantoandro, MD
- Número de teléfono: +261 340600115
- Correo electrónico: andriamiradomoina@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Aged 18 years of age or older.
-
Provision of written informed consent.
-
Laboratory confirmed previous or current Mycobacterium leprae or Mycobacterium lepromatosis infection.
-
Leprosy type 2 reaction meeting the following criteria:
-
Either:
i. Acute (first episode and no treatment initiated) or ii. Recurrent (at least one further episode occurring 28 days or more after withdrawal of leprosy type 2 reaction treatment).
-
Presence of at least 10 leprosy type 2 reaction tender papular and/or nodular skin lesions (not including scars).
-
An ENLIST score of at least 9.
-
-
If a woman of reproductive potential, agree to the use of two reliable contraceptive measures (at least one of which is a highly effective form of contraception) from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care. Refer to Special Considerations for additional information.
-
If male (including those who have had a successful vasectomy), agree to using a latex condom during any sexual contact with women of reproductive potential from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care.
Exclusion Criteria:
-
Chronic leprosy type 2 reaction, defined as the reaction occurring for 24 weeks or more during which a subject has required treatment either continuously or where any treatment free period had been < 28 days.
-
Receipt of thalidomide, lenalidomide, pomalidomide, systemic corticosteroids, clofazimine (> 50 mg/day), apremilast or any other phosphodiesterase (PDE) 4 inhibitor, or immunosuppressive/immunomodulatory treatment within 28 days of Baseline.
-
Receipt of an investigational agent within 28 days of Baseline or 5 half-lives of the investigational agent (whichever is longer).
-
Leprosy type 2 reaction with orchitis, uveitis, iritis, or severe neuritis (Grade 3 or greater severe neuritis).
-
Current diagnosis of leprosy type 1 reaction or Lucio's phenomenon.
-
Current tuberculosis, malaria, cutaneous or visceral leishmaniasis or other serious bacterial, viral, or parasitic infection at Screening or Baseline.
-
Active systemic fungal infection requiring or undergoing treatment.
-
Other than leprosy type 2 reaction, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
-
Other than leprosy type 2 reaction, any other dermatological condition that could, in the opinion of the Investigator, interfere with the study assessments.
-
Chronic hepatitis B, chronic hepatitis C, or human immunodeficiency virus (HIV) positive.
-
Pregnant women or breastfeeding mothers.
-
Use (or planned use) of antimetabolites or alkylating agents, rifampin use more frequent than monthly, phenobarbital, carbamazepine, phenytoin, traditional or herbal preparations (including St. John's wort), foods (including grapefruit) known to affect activity of the cytochrome (CYP)3A4 enzyme; of all strong CYP3A and P-gp inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir, cobicistat, diltiazem; and sensitive substrates of CYP3A4, CYP2C9, CYP2C19, and P-gp. Other CYP3A4, CYP2C9, CYP2C19, and P-gp non-sensitive substrates should be used with caution when concomitantly administered with dovramilast.
-
Known or suspected active substance abuse or a history of substance abuse within 6 months prior to Screening.
-
Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or Randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
-
Current diagnosis of depression, and/or history of suicide ideation
-
History of or presence of cardiac disease, including:
- Clinically significant abnormal electrocardiogram
- QTcF > 450 msec
-
Receipt of a vaccination within 7 days of Baseline.
-
Known or suspected hypersensitivity to: PDE4 inhibitors including dovramilast or apremilast; thalidomide; prednisolone, or; excipients used in the formulation of dovramilast, thalidomide or prednisolone.
-
Body Mass Index < 15 kg/m^2 or > 35 kg/m^2.
-
Unable to, or significant difficulty with, swallowing tablets/capsules.
-
Anemia requiring transfusion.
-
History of or current pancreatitis.
-
Known or suspected cirrhosis of the liver.
-
The following laboratory abnormalities:
- White blood cells (WBC) < 2.5 x 10^9/ L.
- Neutrophils (granulocytes) < 1.0 x 10^9/L.
- Platelets < 80 x 10^9/L.
- Aspartate aminotransferase or alanine aminotransferase > 2 times the upper limit of reference range.
- Albumin < 30 mg/dL.
- Bilirubin > 2 mg/dL
- Calculated creatinine clearance (Cockcroft Gault) < 50 milliliter (mL)/minute.
- Lipase ≥ 1.6 times the upper limit
-
Previous participation in this study
-
Unwilling, unlikely or unable to comply with all protocol specified assessments, including photographic assessments
-
Enrolled in another leprosy type 2 reaction treatment study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Dovramilast 100 mg
|
Dovramilast |
|
Experimental: Dovramilast 150 mg
|
Dovramilast |
|
Comparador activo: Standard of care
Prednisolone (or thalidomide US sites only) |
Standard of care Standard of care (US only) |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The proportion of dovramilast (100 mg or 150 mg) recipients achieving a 75% improvement in leprosy type 2 reaction skin lesions at week 12
Periodo de tiempo: 12 weeks
|
The proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count of at least 75% from Baseline at Week 12 without the need for rescue. Rescue is defined as:
|
12 weeks
|
|
Incidence and severity of adverse events
Periodo de tiempo: 12 weeks
|
The incidence and severity of adverse events, changes in vital signs and blood dyscrasias |
12 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cambio de la línea de referencia (Erythema Nodosum Leprosum International Study) Puntuación de escala de gravedad
Periodo de tiempo: En cada punto de referencia de la línea de base
|
En cada punto de referencia de la línea de base
|
|
|
Cambios en la neuropatía desde el grado de referencia
Periodo de tiempo: 12 semanas
|
12 semanas
|
|
|
Proporción de sujetos que requieren medicamentos de rescate y tiempo para iniciar la medicación de rescate
Periodo de tiempo: 12 semanas
|
12 semanas
|
|
|
Cantidad total de tratamiento para la reacción de la lepra tipo 2 administrada
Periodo de tiempo: 12 semanas
|
12 semanas
|
|
|
Resolution of fever to ≤ Grade 1
Periodo de tiempo: 12 weeks
|
Proportion of subjects with resolution of fever to ≤ Grade 1 among the subgroup of subjects with fever present at Baseline at Grade 2 or greater. |
12 weeks
|
|
Skin lesion count changes
Periodo de tiempo: 12 weeks
|
• Change from Baseline in skin lesion count up to and including Week 12. |
12 weeks
|
|
Change from Baseline of each of the following parameters when present at Baseline at Grade 2 or greater
Periodo de tiempo: from baseline to Week 12
|
|
from baseline to Week 12
|
|
Time to resolution
Periodo de tiempo: 12 weeks
|
For each individual leprosy type 2 reaction when present at least Grade 1 at Baseline |
12 weeks
|
|
Recurrences
Periodo de tiempo: 48 weeks
|
Recurrence is defined as new signs and symptoms consistent with leprosy type 2 reaction. The number of Recurrence episodes requiring treatment. |
48 weeks
|
|
Exposure metrics of dovramilast
Periodo de tiempo: 48 weeks
|
Area under the curve (AUC) |
48 weeks
|
|
Exposure metrics of the dovramilast metabolite M15
Periodo de tiempo: 48 weeks
|
Area under the curve (AUC) |
48 weeks
|
|
Skin lesion count changes
Periodo de tiempo: 12 weeks
|
• Proportion of Responders at each post-Baseline timepoint. |
12 weeks
|
|
Skin lesion count changes
Periodo de tiempo: 12 weeks
|
Proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count from Baseline of 50%, 90% and 100% without Rescue at Week 12. |
12 weeks
|
|
Exposure metrics of dovramilast
Periodo de tiempo: 48 weeks
|
Including AUC, Cmax, and Tmax. |
48 weeks
|
|
Exposure metrics of dovramilast
Periodo de tiempo: 48 weeks
|
Cmax |
48 weeks
|
|
Exposure metrics of dovramilast
Periodo de tiempo: 48 weeks
|
Tmax. |
48 weeks
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Quantification of immunological markers in whole blood samples by central laboratory, blinded to patient identification, treatment arm, and study visit
Periodo de tiempo: 48 weeks
|
Concentration of inflammatory cytokines |
48 weeks
|
|
Quantification of immunological markers in skin biopsies by central laboratory, blinded to patient identification, treatment arm, and study visit
Periodo de tiempo: 48 weeks
|
Leukocyte infiltration of skin lesions by histology |
48 weeks
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Ácidos carboxílicos
- Compuestos policíclicos
- Piperidinas
- Espierra
- Embarazos
- Esteroides
- Compuestos de anillo fusionado
- Esparrazadienetrioles
- Ftalimidas
- Ácidos ftálicos
- Ácidos, carbocíclicos
- Piperidonas
- Isoindoles
- Prednisolona
- Talidomida
Otros números de identificación del estudio
- MDGH-DOV-2001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .